EU Drug Report 2026: Cannabis remains Europe’s most used illicit drug as policy fractures widen

Cannabis still dominates Europe’s illicit-drug picture

The European Union’s latest assessment puts cannabis at the center of the continent’s drug landscape. In the EUDA’s cannabis chapter for the 2026 European Drug Report, the agency says cannabis remains the most commonly used illicit drug in Europe. A separate summary of the report says around 25 million Europeans used cannabis, underlining how large the market remains even as the policy debate grows more complicated.

The report does not describe a static market. Other coverage of the same EUDA release notes that Europe’s drug market is becoming more complex, with new synthetic products gaining ground even as cannabis stays the most familiar illicit substance. That combination matters: cannabis is still the scale leader, but it is now being measured inside a broader landscape of shifting enforcement priorities and changing product risks.

A fragmented legal map keeps shaping access and enforcement

The report’s significance is not just in the usage figures. It also lands in a Europe where there is still no harmonised EU law on illicit cannabis, a point the EUDA has made in its FAQ on cannabis laws in Europe. EU law can set minimum rules for serious cross-border drug trafficking, but day-to-day rules on possession, supply, medical access and cultivation remain national territory.

Germany, France and Hungary show how uneven the debate has become

Three recent European developments capture the range of the current debate. In Germany, cannabis reform remains politically contested, with The Guardian reporting that the health minister called the relaxed policy a mistake and an interim report finding cannabis clubs still play only a minor role. In France, medical access is still in motion: one report says the pilot has been extended to 2027, while other coverage says officials have outlined reimbursement plans but the legislation needed for a lasting framework remains blocked.

Hungary adds a different layer entirely. In January, the Court of Justice of the European Union ruled that Hungary breached EU law by voting against the EU’s common position on cannabis rescheduling at the UN. The case matters beyond the immediate dispute because it shows how cannabis policy can trigger not just domestic argument but also questions about whether member states can break ranks on EU positions in international forums.

• Germany: political arguments continue over the direction and impact of reform.
• France: medical cannabis access has been prolonged, but permanent law is still unresolved.
• Hungary: the EU’s top court found a breach of EU law in a cannabis-related UN vote.

Medical cannabis is expanding, but not in a straight line

Europe’s medical market is one of the clearest signs that cannabis policy is moving, even when adult-use debates remain stalled. A report on Spain says Taima Growth became the country’s fourth AEMPS-licensed medical cannabis cultivator, giving the startup a role in a sector that is still tightly regulated and closely tied to export markets. Elsewhere, a separate piece on England argues that a small number of doctors may be responsible for a large share of private medical cannabis prescribing, a reminder that access can remain highly concentrated even where the market appears established.

The broader European picture is one of fragmentation rather than convergence. A 2026 Chambers guide says Germany remains Europe’s largest medical cannabis market, while France’s broader access framework has repeatedly been delayed. A Muzo Health overview makes the same point more bluntly: national rules, reimbursement systems and cross-border supply still vary widely across the continent. That is also why commercial attention keeps shifting toward regulatory openings rather than a single European market.

Stricter rules are arriving around the edges

While the EUDA report focuses on the broad drug picture, other recent coverage points to a tightening environment around cannabis-related products and enforcement. EURACTIV reported that EU countries are introducing new restrictions on hemp and cannabis-derived foods and flower products, suggesting that regulators are not only dealing with illicit supply but also with the boundaries of semi-legal or consumer-facing cannabis products.

Enforcement pressure is also rising at the political level. EURACTIV said EU leaders are considering tougher action against drug gangs, while MJBizDaily reported that ministers from Germany, Malta, the Netherlands and Luxembourg discussed adult-use cannabis policy hurdles. Those discussions point to a familiar problem: Europe is debating cannabis policy across several overlapping fields at once — policing, health, trade and regulation — without a common adult-use framework to tie them together.

“Status quo not a tenable option” was how ministers framed the policy hurdles, according to MJBizDaily’s report on the meeting.

MJBizDaily

What the new report adds to Europe’s policy argument

Taken together, the EUDA report and the surrounding 2026 coverage show a continent in transition but not in alignment. Cannabis is still the most widely used illicit drug, yet the policy environment around it is moving in different directions at once. Some governments are tightening product rules; others are extending medical pilots; courts are policing the limits of member-state autonomy; and some political actors are still pushing for broader reform, even while others back away from it.

That is why the report matters beyond the annual headline. It does not simply say that cannabis use is widespread. It places that fact inside a Europe where the legal and commercial meaning of cannabis remains unsettled. For readers trying to understand the current situation in Europe, the key point is not just prevalence, but fragmentation: a large market, a moving regulatory target and no single endpoint in sight.